Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by InnoCare Pharma
< Previous
1
2
3
Next >
10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH
November 14, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China
October 26, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib
September 13, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Releases 2023 Interim Results and Business Highlights
August 29, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China
July 25, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China
July 04, 2023
From
InnoCare Pharma
Via
Business Wire
Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML)
June 15, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL
April 19, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China
April 03, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Releases 2022 Annual Results and Business Highlights
March 27, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
March 09, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05
February 23, 2023
From
InnoCare Pharma
Via
Business Wire
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology
February 06, 2023
From
InnoCare Pharma
Via
Business Wire
Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
January 25, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
December 27, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
December 20, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
November 22, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales
November 13, 2022
From
InnoCare Pharma
Via
Business Wire
10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH
November 07, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China
October 31, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
September 20, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China
September 12, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
September 08, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA
September 06, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
August 30, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369
August 23, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Releases 2022 Mid-Year Results and Business Highlights
August 21, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China
August 12, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
August 01, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program
July 21, 2022
From
InnoCare Pharma
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit